Skip to content
lennox

Partner Treatment Library

Peptides

Semax / Selank

Two research peptides discussed for focus, calm, stress resilience, and mental stamina.

Download evidence brief
Lennox Semax / Selank product vial
Common goals
Potential support for focus, calm, stress resilience, mental stamina, and a more balanced mood experience.
Best program fit
May fit a monitored cognitive-wellness offering that tracks concentration, mood, sleep, and daily function.
Format
Clinician-confirmed formulation

Partner education guide

Where this may fit in an offering.

Potential support for focus, calm, stress resilience, mental stamina, and a more balanced mood experience. A non-sedating neuropeptide concept that may appeal to individuals who want cognitive and emotional support without a traditional daily tablet. Intranasal positioning may feel convenient and fast to incorporate into a daily routine.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

  • Potential support for focus, calm, stress resilience, mental stamina, and a more balanced mood experience.
  • A non-sedating neuropeptide concept that may appeal to individuals who want cognitive and emotional support without a traditional daily tablet.
  • Component-level research provides an early rationale for anxiety, attention, and neurologic-recovery goals.

Program value

How it may support a program

  • Intranasal positioning may feel convenient and fast to incorporate into a daily routine.
  • Can fit a clinician-led program that tracks sleep, anxiety, concentration, mood, and functional performance.

Potential benefits come from small, region-limited component studies, preclinical work, and individual reports. The combined product is not FDA-approved and outcomes are not guaranteed.

02 / Program fit

Program and operational considerations.

01Administration
Catalog format: Clinician-confirmed formulation. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency
Frequency is individualized around the exact formulation, individual goals, tolerability, and monitoring plan.
03Expected duration
Use a defined clinician-directed trial period with baseline measures, scheduled reassessment, and a clear continuation or stopping decision.
04Practical advantages
Intranasal positioning may feel convenient and fast to incorporate into a daily routine.

03 / Suitability considerations

Who may be considered.

Who may be considered

  • A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
  • An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

  • Intranasal positioning may feel convenient and fast to incorporate into a daily routine.
  • Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

01

Common or temporary

  • Reliable frequencies are unavailable. Reported or plausible effects include nasal irritation, altered taste, headache, fatigue, dizziness, agitation, irritability, sleep change, and mood change.

02

Serious or important

  • Long-term neuropsychiatric, cardiovascular, reproductive, immune, and drug-interaction safety are not established.
  • Injection or poorly controlled nasal products add contamination, dosing, and product-identity risk.

03

Avoid or use only with specialist input

  • Pregnancy or breastfeeding, active psychosis or mania, severe uncontrolled anxiety or depression, acute neurologic symptoms, or unverifiable product identity.
  • Use as a substitute for urgent stroke care, suicide-risk assessment, or evidence-based psychiatric treatment.

04

Screening checklist

  • Review symptom onset, functional impact, sleep, substance and stimulant use, psychiatric and neurologic history, current medicines and supplements, blood pressure, pregnancy status, and suicide or mania risk.
  • Confirm route and ingredients and create a short, objective outcome plan if research use is considered.

05

When to refer

  • Sudden weakness, speech or vision change, severe new headache, confusion, seizure, suicidality, psychosis, mania, or major functional decline requires urgent or specialist care.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Small, region-limited studies and anecdotes are not enough for broad claims.

01 / Human research

The clearest clinical signal

Small, mostly Russian-language studies report signals for Semax after stroke and Selank for anxiety. Reporting and independent replication are limited. No trial of the pair was found.

02 / Real-world reports

What people describe

About 12 detailed accounts were sampled. Some described calm focus within minutes to days. Others felt nothing. Headache, irritability, low mood, fatigue, nasal irritation, and a short-lived effect were common disagreements.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Headache, agitation, tiredness, mood change, nasal irritation, unknown drug interactions, and unknown long-term brain safety. The exact dose, sterility, purity, and label accuracy matter.

Does the research match this exact product?

Condition-specific studies of separate peptides do not match an unspecified combined product.

Research and regulatory context

A randomized comparative study enrolled 62 individuals with anxiety-spectrum diagnoses and compared Selank with medazepam, but the accessible report does not provide a placebo-controlled demonstration for broad use. Evidence for Semax is condition-specific and difficult to generalize, and the combination has not been directly tested.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Download the evidence briefPDF · larger type

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments